Search clinical trials for: Nintedanib (BIBF1120)

Total 175 results

Boehringer Ingelheim

Completed

A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer

Ovarian Neoplasms

United Kingdom
Ulrik Lassen
University of Copenhagen; Boehringer Ingelheim

Completed

BIBF 1120 in Recurrent Glioblastoma Multiforme

Recurrent Glioblastoma

Denmark
AHS Cancer Control Alberta
Boehringer Ingelheim; Cross Cancer Institute

Withdrawn

A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy

Small Cell Lung Cancer | Platinum-sensitive

Canada
Samsung Medical Center

Unknown

Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck

Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck

Korea, Republic of
National Taiwan University Hospital

Unknown

BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma

Urothelial Carcinoma

Taiwan
University Hospital Muenster
Boehringer Ingelheim

Unknown

Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Germany
European Organisation for Research and Treatment...

Completed

Nintedanib(BIBF1120) in Thyroid Cancer

Differentiated Thyroid Cancer (DTC) | Medullary Thyroid Cancer (MTC)

France, Belgium, Denmark, Italy, Netherlands, Germany, Poland, Spain, United Kingdom
European Organisation for Research and Treatment...
Boehringer Ingelheim

Terminated

Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma (ANITA)

Sarcoma, Soft Tissue

France, Belgium, Poland, Spain, Lithuania, Netherlands, United Kingdom
University of Alabama at Birmingham
Boehringer Ingelheim

Completed

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

Renal Cell Carcinoma | Non-squamous Non-small Cell Lung Cancer | Cervical Carcinoma | Colorectal Adenocarcinoma | Platinum-refractory Ovarian Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Lung Cancer, Nonsmall Cell

United States
Boehringer Ingelheim

Completed

Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Japan
Boehringer Ingelheim

Completed

Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis

Pulmonary Fibrosis

Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czech Republic, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation, South Africa, Spain, Taiwan and more
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether Four Capsules of 25 mg Nintedanib Are Taken up in the Body in the Same Way as One 100 mg Capsule

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib

Healthy

United Kingdom
Sixth Affiliated Hospital, Sun Yat-sen University

Not yet recruiting

Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions

Uterine Adhesions
Wake Forest University Health Sciences
Boehringer Ingelheim

Terminated

LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma

Appendix Cancer

United States
Boehringer Ingelheim

Completed

Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment

Idiopathic Pulmonary Fibrosis

Spain, Korea, Republic of, Belgium, Czechia, Australia, Germany, United Kingdom, United States, France, Finland, Japan, Poland, Hungary
Boehringer Ingelheim

Approved for marketing

Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)

Idiopathic Pulmonary Fibrosis

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

Recurrent Pleural Malignant Mesothelioma | Stage IV Pleural Mesothelioma

United States
Boehringer Ingelheim

Active, not recruiting

A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)

Lung Diseases, Interstitial

United States, Spain, United Kingdom, Canada, Finland, Norway, Italy, Argentina, Belgium, Brazil, Czechia, France, Greece, Mexico, Poland, Germany, Portugal
Boehringer Ingelheim

No longer available

A Treatment Protocol to Support the Care of Children and Adolescents With Fibrosing Interstitial Lung Disease (ILD)

Lung Diseases, Interstitial (in Pediatric Populations) | Childhood Interstitial Lung Disease (chILD)
Boehringer Ingelheim

No longer available

Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Brazil
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm

United States
Boehringer Ingelheim

Active, not recruiting

A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis

Lung Diseases, Interstitial

China
McGill University Health Centre/Research Institute...

Recruiting

Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease: a Pilot Study

Interstitial Lung Disease | Myopathy, Inflammatory

Canada
Holdsworth House Medical Practice
Boehringer Ingelheim

Recruiting

The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial (NiPPs)

Silicosis | Pneumoconiosis Coal | Asbestosis

Australia
Huilan Zhang

Unknown

Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19

COVID-19 | Safety | Effect of Drugs | Nintedanib
Endeavor Biomedicines, Inc.

Completed

A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

Idiopathic Pulmonary Fibrosis

Australia
Boehringer Ingelheim

No longer available

An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment Options

Lung Diseases, Interstitial

Belgium
Boehringer Ingelheim

Completed

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

Colorectal Neoplasms

United States, Argentina, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hong Kong, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Taiwan, T... and more
Assistance Publique - Hôpitaux de Paris
Boehringer Ingelheim

Recruiting

Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis (NINTECOR)

SARS-Cov-2 Induced Pulmonary Fibrosis

France
University College, London
Boehringer Ingelheim

Completed

Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer (METRO-BIBF)

Ovarian Cancer | Fallopian Tube Cancer

United Kingdom
Boehringer Ingelheim

Completed

Relative Bioavailability of 2 Oral Formulations of Nintedanib

Healthy

Germany
Boehringer Ingelheim

Completed

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

Carcinoma, Non-Small-Cell Lung

Germany, Canada, United States, Hong Kong, Taiwan, Brazil, Korea, Republic of, Peru, Poland, Ukraine, Thailand, Argentina, Australia, New Zealand, Sweden, Hungary, Turkey, Serbia, Bosnia and Herzegovina, Chile, Colombia, Ecuador, Ir... and more
AIO-Studien-gGmbH

Completed

Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology (NintNivo)

Adenocarcinoma of the Lung

Germany
Yale University
Vanderbilt University

Completed

A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia

United States
Boehringer Ingelheim

Terminated

LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research

Carcinoma, Non-Small-Cell Lung

United States, Georgia, Thailand
Hospices Civils de Lyon

Recruiting

Management of Progressive Disease in Idiopathic Pulmonary Fibrosis (PROGRESSION)

Progressive Idiopathic Pulmonary Fibrosis

France
Prof. Dr. med. Dirk Schadendorf
Boehringer Ingelheim; medac GmbH; Alcedis GmbH

Completed

Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma (NIPAWILMA)

Cutaneous Malignant Melanoma

Germany
China Medical University Hospital

Not yet recruiting

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Non-small Cell Lung Cancer | EGFR Gene Mutation | EGFR-TKI Resistant Mutation
Hal Chapman
Massachusetts General Hospital; University of Michigan; University of Washington and other collaborators

Recruiting

Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

Idiopathic Pulmonary Fibrosis

United States
Hospices Civils de Lyon

Completed

Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease. (EPICURE)

Telangiectasia, Hereditary Hemorrhagic | Rendu Osler Disease

France
Nordic Society of Gynaecological Oncology - Clinical...
ARCAGY/ GINECO GROUP; Belgian Gynaecological Oncology Group; North Eastern German...

Completed

Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer

Endometrial Cancer

France, Belgium, Germany, Norway, Finland, Sweden, Denmark
Roswell Park Cancer Institute
National Cancer Institute (NCI); Boehringer Ingelheim

Completed

Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Stage III Non-small Cell Lung Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Boehringer Ingelheim; National Comprehensive...

Completed

Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal Cancer

United States
Boehringer Ingelheim

Completed

Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain

Idiopathic Pulmonary Fibrosis

Spain
University Hospital, Basel, Switzerland

Recruiting

Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (NINBOST2018)

Bronchiolitis Obliterans Syndrome (BOS) | Bronchiolitis Obliterans (BO)

Switzerland, Saudi Arabia
Children's Hospital Medical Center, Cincinnati

Active, not recruiting

Pharmacokinetic and Pharmacodynamic Analysis of Ceftaroline in Children and Adolescents With Cystic Fibrosis

Cystic Fibrosis

United States
Memorial Sloan Kettering Cancer Center

Completed

Nintedanib in Patients With Advanced Esophagogastric Cancer

Esophagogastric Adenocarcinoma

United States
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Completed

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Carcinoid Tumor | Neuroendocrine Neoplasm | Metastatic Carcinoid Tumor

United States

Search clinical trials for: Nintedanib (BIBF1120)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations